The following is a searchable and filterable list of our news posts, press releases, white papers, articles, scientific posters, and much more.
If you can’t find something, please let us know and we’ll reach out to you as soon as we can.
Determination of endometrial cancer molecular subtypes using a whole exome-sequencing based single-method approach
J Cancer Res Clin Oncol 150, 367 (2024). https://doi.org/10.1007/s00432-024-05901-4Open resourceIntegrated DNA Technologies and Molecular Health Ink Commercial Partnership
Strategic partnership enables companies to combine technology offerings and streamline NGS workflowsRead moreA multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC
Schell, MJ. Nat Commun. 2016;7:11743Open resourceBioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer
Malgerud, L. et al. Mol Oncol. 2017;11(10):1413-1429Open resourceConsolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide
Hirotsu, Y. et al. Int J Mol Sci. 2020;21(11):3895Open resourceWhole Exome Analysis to Select Targeted Therapies for Patients with Metastatic Breast Cancer – A Feasibility Study
Jaeger, BAS. Geburtshilfe Frauenheilkd. 2023;83(9):1138-1147Open resourceRewiring Drug Research and Development through Human Data-Driven Discovery (HD3)
Jackson, D.B. et al. Pharmaceutics 2023, 15(6), 1673Open resourceDetermination of the Cancer Genome Atlas (TCGA) Endometrial Cancer Molecular Subtypes Using the Variant Interpretation and Clinical Decision Support Software MH Guide
Mustea, A. et al. Cancers 2023, 15(7), 2023Open resourceCurrently no job listings
Read moreWhole patient knowledge modeling of COVID-19 symptomatology reveals common molecular mechanisms
Brock, S. et al. Front. Mol. Med. 2023, 2:1035290. https://doi.org/10.3389/fmmed.2022.1035290Open resourceAdvancing drug safety science by integrating molecular knowledge with post‐marketing adverse event reports
Soldatos, T. G. et al. CPT Pharmacometrics Syst Pharmacol. 2022 May;11(5):540-555. doi: 10.1002/psp4.12765Open resourceEvaluation of the TruSight Tumor 170 Assay and Its Value in Clinical Diagnostics
Heydt, C. et al. J. Mol. Pathol. 2022, 3(1), 53-67; https://doi.org/10.3390/jmp3010006Open resourceApplication of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors
Kim, S. et al. Clin Transl Sci. 2022 Jun;15(6):1430-1438. doi: 10.1111/cts.13254Open resourceThe COVID-19 explorer – An integrated, whole patient knowledge model of COVID-19 disease
Brock, S. et al. Front. Mol. Med. 2022, 2:1035215. https://doi.org/10.3389/fmmed.2022.1035215Open resourceTarget adverse event profiles for predictive safety in the postmarket setting
Peter Schotland, Rebecca Racz, David B. Jackson, Theodoros G. Soldatos, Robert Levin, David G. Strauss and Keith Burkhart. Clinical Pharmacology & Therapeutics Volume 109, Issue 5, Pages: 1159-1362 (May 2021)Open resourceA case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development
Kim, S. et al. Clin Transl Sci . 2022 Apr;15(4):1003-1013. doi: 10.1111/cts.13219Open resource